Search
Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15740InvestigationalCurrently, OM-MSCs does not have wide application as there is not yet a standard and unambiguous protocol for OM-MSC collection, isolation, and therapeutic application.
Topiroxostat
go.drugbank.com/drugs/DB01685InvestigationalWhile [DB00437] is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens
Resolvin E1
go.drugbank.com/drugs/DB13105InvestigationalResolvin E1 (RX 10001) is under investigation in clinical trial NCT00941018 (Single and Multiple Ascending Oral Dose Study of Resolvin E1 in Healthy Volunteers).
Crotalus scutulatus antivenin
go.drugbank.com/drugs/DB13891ApprovedIt is intravenously administered to limit systemic toxicity [FDA label], [L2857], [L2858]. … Since it was approved by the Food and Drug Administration in October 2000, crotalidae poyvalent immune Fab (CroFab) has largely replaced previously used crotaline antivenom.
Lumefantrine co-artemether
go.drugbank.com/drugs/DB13085ApprovedInvestigationalWithdrawnWhile artemether results in rapid defervescence, parasite clearance, and clinical improvement, it also has a relatively high recrudescence rate when used as monotherapy. … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.
Catridecacog
go.drugbank.com/drugs/DB09310ApprovedCoagulation Factor XIII A-Subunit (Recombinant) is available in the US as the commmercially available product Tretten, and in the EU as NovoThirteen. … When activated by thrombin at the site of injury, the FXIII A2B2 pro-enzyme is cleaved resulting in activation of the catalytic A-subunit and dissociation from its carrier B-subunit.
Tranylcypromine
go.drugbank.com/drugs/DB00752ApprovedInvestigationalIt also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311).
Zalcitabine
go.drugbank.com/drugs/DB00943ApprovedWithdrawnThe compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase.
Gilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.
Products: XOSPATA® FILM-COATED TABLETS 40MG, Xospata 40mg Film Coated TabletsTertomotide
go.drugbank.com/drugs/DB12747InvestigationalIt is a peptide vaccine that activates the immune system so that it recognizes and kills cancer cells. It is being developed by Pharmexa A/S.